Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

GSI Group generates revenue of $85.5 million during third quarter 2013

GSI Group Inc., a global leader and supplier of precision photonics and motion control components and subsystems to the medical, industrial, electronics and scientific markets, today reported financial results for the third quarter of 2013.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

New research may lead to novel approaches for preventing tissue injury during cryopreservation

Developing an efficient way to freeze and store living tissues could transform many aspects of medical care and research, but ice crystallization often occurs within cells during such cryopreservation procedures, leading to cell death.

6 Nov 2013

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of Fiscal 2014 (ended September 30, 2013).

6 Nov 2013

Life Technologies revenue for third quarter increases 3% to $936

Life Technologies Corporation (NASDAQ: LIFE) today announced results for its third quarter ended September 30, 2013. Revenue for the third quarter was $936 million, an increase of 3 percent over the $911 million reported for the third quarter of 2012.

5 Nov 2013

Reviva announces successful completion of End-of-Phase 2 meeting for RP5063 drug

Reviva Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the discovery and development of new, safer and highly effective therapies for chronic indications, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration for its lead, new investigational antipsychotic drug, RP5063.

5 Nov 2013

Zevacor Molecular buys 70 MeV Cyclotron dedicated to medical use from IBA

Zevacor Molecular, an independently owned healthcare firm that manufactures and distributes PET and SPECT radiopharmaceuticals, has purchased the first 70 MeV Cyclotron dedicated to medical use in the United States from Ion Beam Applications, S.A.

5 Nov 2013

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII.

4 Nov 2013

Alkermes reports 38% of year-over-year revenue growth from key products

Alkermes plc today reported financial results for the quarter ended Sept. 30, 2013. This is the second quarter of the nine-month period ending Dec. 31, 2013, as the company transitions to reporting on a calendar year basis.

31 Oct 2013

Bestnet to distribute DuraNet Long Lasting Insecticide Nets

Bestnet A/S announced today that the company has entered into an agreement with Shobikaa Impex Pvt Ltd. in regard to DuraNet® Long Lasting Insecticide Nets (LLINs).

29 Oct 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Haemonetics net revenue increases 8% to $235.8 million in Q2 fiscal 2014

Haemonetics Corporation today reported second quarter fiscal 2014 net revenue of $235.8 million, up 8%, GAAP net income of $16.5 million and earnings per share of $0.32. Adjusted net income, exclusive of transformation, integration and deal amortization expenses detailed below, was $34.4 million, up 24%, and adjusted earnings per share were $0.66, up 24%. Excluding currency impact, net revenue was up 11% in the quarter.

28 Oct 2013

Researchers develop robots for bridge inspection, mine rescue, aid for blind

Robotic rotorcraft for inspecting bridges and other infrastructure, tools for minimally invasive surgery that guide surgeons by creating 3D maps of internal organs and assistive robots for blind travelers are among seven new Carnegie Mellon University research projects sponsored through the National Robotics Initiative.

25 Oct 2013

DSM, Sanquin Make Factor IX-Recovering Mab Manufacturing Deal

...

24 Oct 2013

Mckesson's $8.3B Celesio Deal Builds Drug Warehousing Powerhouse

...

24 Oct 2013

Zimmer Holdings net sales increase 4.8% to $1.07 billion in Q3 2013

Zimmer Holdings, Inc. today reported financial results for the quarter ended September 30, 2013. The Company reported third quarter net sales of $1.07 billion, an increase of 4.8% reported and 6.7% constant currency over the third quarter of 2012

24 Oct 2013

McKesson agrees to acquire majority stake in Celesio

McKesson Corporation, a leading North American healthcare services and information technology company, and Celesio AG, a leading international wholesale and retail company and provider of logistics and services to the pharmaceutical and healthcare sectors, announced today that McKesson has signed an agreement to acquire a majority stake in Celesio for €23 per share and to launch parallel voluntary public tender offers for the remaining publicly-traded shares and outstanding convertible bonds of Celesio.

24 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

FDA seeks permanent injunction against dietary supplement manufacturer James G. Cole

The U.S. Food and Drug Administration, in a complaint filed by the U.S. Department of Justice, is seeking a permanent injunction against the dietary supplement manufacturer James G. Cole, Inc., its president, James G. Cole, and its general manager, Julie D. Graves, following the company's repeated distribution of unapproved drugs and adulterated dietary supplements in violation of the Federal Food, Drug, and Cosmetic Act.

23 Oct 2013